Cytomegalovirus-specific CD4 T cells are cytolytic and mediate vaccine protection

Journal of Virology

Volumn 90, Issue 2, 2016, Pages 650-658

  Verma, Shilpi ^a   Weiskopf, Daniela ^a   Gupta, Ankan ^a   McDonald, Bryan ^a   Peters, Bjoern ^a   Sette, Alessandro ^a   Benedict, Chris A ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; EPITOPE; GRANZYME B; M53 [285-299] PEPTIDE; M78 [417-431] PEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; UNCLASSIFIED DRUG; GRANZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HOST RESISTANCE; IMMUNOCOMPETENCE; IN VIVO STUDY; INFECTION PREVENTION; INNATE IMMUNITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MUROMEGALOVIRUS; TOMBUSVIRIDAE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CYTOMEGALOVIRUS VACCINES; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; MICE, INBRED BALB C; MUROMEGALOVIRUS; TOMBUSVIRIDAE;

EID: 84954113947     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02123-15     Document Type: Article

References (53)

1. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. 2006. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43:1143-1151. http://dx.doi.org/10.1086/508173.
2. Pereira L, Maidji E, McDonagh S, Tabata T. 2005. Insights into viral transmission at the uterine-placental interface. Trends Microbiol 13:164-174. http://dx.doi.org/10.1016/j.tim.2005.02.009.
3. Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102-3108.
4. Kurz S, Steffens HP, Mayer A, Harris JR, Reddehase MJ. 1997. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol 71:2980-2987.
5. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, Hamprecht K, Handgretinger R, Lang P, Einsele H. 2010. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116:4360-4367. http://dx.doi.org/10.1182/blood-2010-01-262089.
6. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S. 2003. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virusspecific T-cell lines. Lancet 362:1375-1377. http://dx.doi.org/10.1016/S0140-6736(03)14634-X.
7. Reddehase MJ, Jonjic S, Weiland F, Mutter W, Koszinowski UH. 1988. Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J Virol 62:1061-1065.
8. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.NEngl J Med 333:1038-1044. http://dx.doi.org/10.1056/NEJM199510193331603.
9. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. 2003. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+T cells in protection against CMV disease. Blood 101:2686-2692. http://dx.doi.org/10.1182/blood-2002-08-2502.
10. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM. 1998. Restoration of cytomegalovirusspecific CD4+T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:953-956. http://dx.doi.org/10.1038/nm0898-953.
11. Sester M, Sester U, Gartner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Kohler H. 2001. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287-1294. http://dx.doi.org/10.1097/00007890-200105150-00018.
12. Lilleri D, Fornara C, Revello MG, Gerna G. 2008. Human cytomegalovirus-specific memory CD8+ and CD4+ T cell differentiation after primary infection. J Infect Dis 198:536-543. http://dx.doi.org/10.1086/590118.
13. Tu W, Chen S, Sharp M, Dekker C, Manganello AM, Tongson EC, Maecker HT, Holmes TH, Wang Z, Kemble G, Adler S, Arvin A, Lewis DB. 2004. Persistent and selective deficiency of CD4+T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 172: 3260-3267. http://dx.doi.org/10.4049/jimmunol.172.5.3260.
14. Lucin P, Pavic I, Polic B, Jonjic S, Koszinowski UH. 1992. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol 66:1977-1984.
15. Polic B, Hengel H, Krmpotic A, Trgovcich J, Pavic I, Luccaronin P, Jonjic S, Koszinowski UH. 1998. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188:1047-1054. http://dx.doi.org/10.1084/jem.188.6.1047.
16. Jeitziner SM, Walton SM, Torti N, Oxenius A. 2013. Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection. Eur J Immunol 43:2886-2895. http://dx.doi.org/10.1002/eji.201343690.
17. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916-3922. http://dx.doi.org/10.1182/blood.V99.11.3916.
18. Brown DM. 2010. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 262:89-95. http://dx.doi.org/10.1016/j.cellimm.2010.02.008.
19. Marshall NB, Swain SL. 2011. Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol 2011:954602. http://dx.doi.org/10.1155/2011/954602.
20. Soghoian DZ, Streeck H. 2010. Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines 9:1453-1463. http://dx.doi.org/10.1586/erv.10.132.
21. Elkington R, Shoukry NH, Walker S, Crough T, Fazou C, Kaur A, Walker CM, Khanna R. 2004. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 34:3216-3226. http://dx.doi.org/10.1002/eji.200425203.
22. Fleischer B. 1984. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 308:365-367. http://dx.doi.org/10.1038/308365a0.
23. Hammoud B, Schmueck M, Fischer AM, Fuehrer H, Park SJ, Akyuez L, Schefold JC, Raftery MJ, Schonrich G, Kaufmann AM, Volk HD, Reinke P. 2013. HCMV-specific T-cell therapy: do not forget supply of help. J Immunother 36:93-101. http://dx.doi.org/10.1097/CJI.0b013e31827b87cc.
24. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ, Roederer M, Douek DC, Koup RA. 2006. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 203:2865-2877. http://dx.doi.org/10.1084/jem.20052246.
25. Suni MA, Ghanekar SA, Houck DW, Maecker HT, Wormsley SB, Picker LJ, MossRB,MainoVC. 2001.CD4(+)CD8(dim)Tlymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol 31:2512-2520. http://dx.doi.org/10.1002/1521-4141(200108)31:8<2512::AID-IMMU2512>3.0.CO;2-M.
26. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, ten Berge IJ, van Lier RA. 2006. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 108: 3121-3127. http://dx.doi.org/10.1182/blood-2006-03-006809.
27. Brien JD, Uhrlaub JL, Nikolich-Zugich J. 2008. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J Immunol 181:8568-8575. http://dx.doi.org/10.4049/jimmunol.181.12.8568.
28. Hildemann SK, Eberlein J, Davenport B, Nguyen TT, Victorino F, Homann D. 2013. High efficiency of antiviral CD4(+) killer T cells. PLoS One 8:e60420. http://dx.doi.org/10.1371/journal.pone.0060420.
29. Jellison ER, Kim SK, Welsh RM. 2005. Cutting edge: MHC class IIrestricted killing in vivo during viral infection. J Immunol 174:614-618. http://dx.doi.org/10.4049/jimmunol.174.2.614.
30. Stuller KA, Flano E. 2009. CD4 T cells mediate killing during persistent gammaherpesvirus 68 infection. J Virol 83:4700-4703. http://dx.doi.org/10.1128/JVI.02240-08.
31. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, Sette A, Shresta S. 2010. CD4+ T cells are not required for the induction of dengue virus-specific CD8+T cell or antibody responses but contribute to protection after vaccination. J Immunol 185:5405-5416. http://dx.doi.org/10.4049/jimmunol.1001709.
32. Brown DM, Dilzer AM, Meents DL, Swain SL. 2006. CD4 T cellmediated protection from lethal influenza: perforin and antibodymediated mechanisms give a one-two punch. J Immunol 177:2888-2898. http://dx.doi.org/10.4049/jimmunol.177.5.2888.
33. Jordan S, Krause J, Prager A, Mitrovic M, Jonjic S, Koszinowski UH, Adler B. 2011. Virus progeny of murine cytomegalovirus bacterial artificial chromosome pSM3fr show reduced growth in salivary glands due to a fixed mutation of MCK-2. J Virol 85:10346-10353. http://dx.doi.org/10.1128/JVI.00545-11.
34. Verma S, Wang Q, Chodaczek G, Benedict CA. 2013. Lymphoid-tissue stromal cells coordinate innate defense to cytomegalovirus. J Virol 87: 6201-6210. http://dx.doi.org/10.1128/JVI.00113-13.
35. Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, Kolla RV, De Silva AD, de Silva AM, Grey H, Peters B, Shresta S, Sette A. 2011. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol 187:4268-4279. http://dx.doi.org/10.4049/jimmunol.1101970.
36. Verma S, Loewendorf A, Wang Q, McDonald B, Redwood A, Benedict CA. 2014. Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense. PLoS Pathog 10: e1004268. http://dx.doi.org/10.1371/journal.ppat.1004268.
37. Pepper M, Linehan JL, Pagan AJ, Zell T, Dileepan T, Cleary PP, Jenkins MK. 2010. Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells. Nat Immunol 11:83-89. http://dx.doi.org/10.1038/ni.1826.
38. Rawlinson WD, Farrell HE, Barrell BG. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 70:8833-8849.
39. Arens R, Wang P, Sidney J, Loewendorf A, Sette A, Schoenberger SP, Peters B, Benedict CA. 2008. Cutting edge: murine cytomegalovirus induces a polyfunctional CD4 T cell response. J Immunol 180:6472-6476. http://dx.doi.org/10.4049/jimmunol.180.10.6472.
40. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. 2006. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 177:450-458. http://dx.doi.org/10.4049/jimmunol.177.1.450.
41. McDermott DS, Varga SM. 2011. Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think. J Immunol 187:5568-5576. http://dx.doi.org/10.4049/jimmunol.1102104.
42. Walton SM, Mandaric S, Torti N, Zimmermann A, Hengel H, Oxenius A. 2011. Absence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells. PLoS Pathog 7:e1002214. http://dx.doi.org/10.1371/journal.ppat.1002214.
43. Streeck H, D'Souza MP, Littman DR, Crotty S. 2013. Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med 19:143-149. http://dx.doi.org/10.1038/nm.3054.
44. Kurtz JR, Petersen HE, Frederick DR, Morici LA, McLachlan JB. 2014. Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effector protein provides protection against lethal infection. Infect Immun 82:2424-2433. http://dx.doi.org/10.1128/IAI.00052-14.
45. Ebert S, Lemmermann NA, Thomas D, Renzaho A, Reddehase MJ, Holtappels R. 2012. Immune control in the absence of immunodominant epitopes: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells. Med Microbiol Immunol 201:541-550. http://dx.doi.org/10.1007/s00430-012-0268-8.
46. Brizic I, Lenac Rovis T, Krmpotic A, Jonjic S. 2014. MCMV avoidance of recognition and control by NK cells. Semin Immunopathol 36:641-650. http://dx.doi.org/10.1007/s00281-014-0441-9.
47. Scalzo AA, Yokoyama WM. 2008. Cmv1 and natural killer cell responses to murine cytomegalovirus infection. Curr Top Microbiol Immunol 321: 101-122.
48. Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, Scalzo AA, Smyth MJ, Degli-Esposti MA. 2010. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med 207:1333-1343. http://dx.doi.org/10.1084/jem.20091193.
49. Mitrovic M, Arapovic J, Jordan S, Fodil-Cornu N, Ebert S, Vidal SM, Krmpotic A, Reddehase MJ, Jonjic S. 2012. The NK cell response to mouse cytomegalovirus infection affects the level and kinetics of the early CD8(+) T-cell response. J Virol 86:2165-2175. http://dx.doi.org/10.1128/JVI.06042-11.
50. Cabrera-Perez J, Condotta SA, James BR, Kashem SW, Brincks EL, Rai D, Kucaba TA, Badovinac VP, Griffith TS. 2015. Alterations in antigenspecific naive CD4 T cell precursors after sepsis impairs their responsiveness to pathogen challenge. J Immunol 194:1609-1620. http://dx.doi.org/10.4049/jimmunol.1401711.
51. Naito T, Taniuchi I. 2010. The network of transcription factors that underlie the CD4 versus CD8 lineage decision. Int Immunol 22:791-796. http://dx.doi.org/10.1093/intimm/dxq436.
52. Wang L, Wildt KF, Castro E, Xiong Y, Feigenbaum L, Tessarollo L, Bosselut R. 2008. The zinc finger transcription factor Zbtb7b represses CD8-lineage gene expression in peripheral CD4+ T cells. Immunity 29: 876-887. http://dx.doi.org/10.1016/j.immuni.2008.09.019.
53. Reis BS, Rogoz A, Costa-Pinto FA, Taniuchi I, Mucida D. 2013. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4(+) T cell immunity. Nat Immunol 14:271-280. http://dx.doi.org/10.1038/ni.2518.